Novavax (NASDAQ:NVAX) Now Covered by HC Wainwright

HC Wainwright started coverage on shares of Novavax (NASDAQ:NVAX) in a research report report published on Thursday morning, MarketBeat reports. The firm issued a buy rating and a $10.00 price objective on the biopharmaceutical company’s stock.

NVAX has been the topic of a number of other reports. Citigroup started coverage on shares of Novavax in a research report on Tuesday, June 17th. They set a “sell” rating and a $6.00 target price on the stock. Bank of America reaffirmed an “underperform” rating and set a $7.00 price target (down from $9.00) on shares of Novavax in a report on Wednesday, August 20th. JPMorgan Chase & Co. decreased their price target on Novavax from $9.00 to $7.00 and set an “underweight” rating for the company in a report on Friday, May 9th. Finally, B. Riley reaffirmed a “buy” rating on shares of Novavax in a report on Monday, May 19th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $14.29.

Novavax Stock Performance

Shares of NVAX opened at $7.58 on Thursday. The company has a current ratio of 2.36, a quick ratio of 2.34 and a debt-to-equity ratio of 5.93. The firm has a market cap of $1.23 billion, a PE ratio of 3.32, a price-to-earnings-growth ratio of 0.10 and a beta of 2.50. The company’s 50 day simple moving average is $7.38 and its 200-day simple moving average is $7.17. Novavax has a 12-month low of $5.01 and a 12-month high of $15.22.

Novavax (NASDAQ:NVAX) last announced its earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.69. The business had revenue of $239.24 million for the quarter, compared to analyst estimates of $149.19 million. Novavax had a net margin of 39.20% and a negative return on equity of 142.33%. The company’s revenue for the quarter was down 42.4% compared to the same quarter last year. During the same period last year, the firm posted $0.99 earnings per share. As a group, equities analysts predict that Novavax will post -1.46 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Deutsche Bank AG raised its stake in shares of Novavax by 47.5% during the 4th quarter. Deutsche Bank AG now owns 123,581 shares of the biopharmaceutical company’s stock worth $994,000 after buying an additional 39,787 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Novavax by 10.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 101,812 shares of the biopharmaceutical company’s stock worth $817,000 after buying an additional 9,711 shares during the last quarter. California State Teachers Retirement System raised its stake in shares of Novavax by 12.3% during the 4th quarter. California State Teachers Retirement System now owns 135,486 shares of the biopharmaceutical company’s stock worth $1,089,000 after buying an additional 14,853 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Novavax by 19.8% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 268,684 shares of the biopharmaceutical company’s stock worth $2,160,000 after buying an additional 44,359 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC raised its stake in shares of Novavax by 44.9% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 27,283 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 8,454 shares during the last quarter. Institutional investors and hedge funds own 53.04% of the company’s stock.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.